Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13141516 | 0.83 | ALDH1A1 (0.49) | ALDH1A1TSHRPOLBCYP2C19LMNA | |
| SCHEMBL10051931 | 0.79 | TSHR (0.45) | ALDH1A1TSHRKDM4EHTTL3MBTL1 | |
| SCHEMBL1096745 | 0.77 | KDM4E (0.47) | ALDH1A1TSHRKDM4EHTTPOLB | |
| SCHEMBL31502919 | 0.70 | MAPT (0.49) | ALDH1A1HTT | |
| SCHEMBL31502943 | 0.69 | PKM (0.51) | ALDH1A1TSHRKDM4EHTTPOLB | |
| SCHEMBL13141514 | 0.69 | KMT2A (0.49) | ALDH1A1TSHRCYP2C19LMNAMEN1 | |
| SCHEMBL31502953 | 0.68 | MDM2 (0.53) | ALDH1A1HTT | |
| SCHEMBL31502926 | 0.68 | FFAR1 (0.43) | KDM4EPOLBLMNAMEN1KMT2A | |
| Bicarbonate SCHEMBL14811674 | 0.67 | ALDH1A1 (0.58) | ALDH1A1TSHRKDM4EL3MBTL1HPGD | |
| SCHEMBL10554268 | 0.66 | TSHR (0.56) | ALDH1A1TSHRKDM4EHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122910-A1 | METHOD OF TREATING CANCER USING A SURVIVIN INHIBITOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122910-A1 | METHOD OF TREATING CANCER USING A SURVIVIN INHIBITOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-05-17 | — | — | US | disclosed |
| WO-2010083505-A1 | METHOD OF TREATING CANCER USING A SURVIVIN INHIBITOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122910-A1 | METHOD OF TREATING CANCER USING A SURVIVIN INHIBITOR | BIRC5, CDC20, CCNB1 | ALDH1A1 1765/4885TSHR 4503/4885KDM4E 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.